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Abstract
The prevalence of human papillomavirus (HPV)–associated head and neck cancers is increasing, but the prevalence of oral
HPV infection in the wider community remains unknown. We sought to determine the prevalence of, and identify risk
factors for, oral HPV infection in a sample of young, healthy Australians. For this study, we recruited 307 Australian university
students (18–35 years). Participants reported anonymously about basic characteristics, sexual behaviour, and alcohol,
tobacco and illicit drugs use. We collected oral rinse samples from all participants for HPV testing and typing. Seven of 307
(2.3%) students tested positive for oral HPV infection (3 HPV-18, one each of HPV-16, -67, -69, -90), and six of them were
males (p = 0.008). Compared to HPV negative students, those with oral HPV infection were more likely to have received oral
sex from more partners in their lifetime (p = 0.0004) and in the last year (p = 0.008). We found no statistically significant
associations with alcohol consumption, smoking or numbers of partners for passionate kissing or sexual intercourse. In
conclusion, oral HPV infection was associated with male gender and receiving oral sex in our sample of young Australians.
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Introduction
The incidence of squamous cell carcinoma of the head and neck
(HNSCC), more specifically of oropharyngeal squamous cell
carcinoma (OPSCC), is increasing. Sites particularly affected are
those of the tonsils and base of tongue [1–3]. While previously
most of these cancers could be attributed to tobacco and alcohol, it
appears that recently fewer patients have been presenting with
these classical risk factors. During the last decade there has been a
sizeable increase in the numbers of OPSCCs associated with
human papillomavirus (HPV), and these patients are more often
non-smokers, and often somewhat younger than those with HPV
negative OPSCC [2–7]. This is believed to reflect an increasing
prevalence of oral HPV infections due to changing sexual practices
[4,5]. HPV-16 is the most common high-risk HPV type identified
in oral samples from the general population as well as in HNSCC
tumours [5,8–10]. Oral HPV infection has been strongly
implicated as being responsible for the increase in HNSCC and
is the likely causative factor of the increasing subset of HNSCC
among young non-smokers, but very little is known about the
epidemiology of oral HPV infections. Previous studies have shown
varying oral a-HPV prevalence in different populations, ranging
from 0.6% (4/662) in a Japanese study of a sample of the
population of Miyako Island up to 25% (29/117) in an American
study of older men [10–14]. The largest study to date reported an
overall oral HPV prevalence of 6.9% among 5,579 men and
women, aged 14 to 69 years in the United States [10]. The
prevalence of oral infection in the general population of Australia
remains unknown. We analysed a-HPV DNA prevalence and
HPV types together with life-style factors and sexual behaviour in
a sample of young, healthy Australians, and herewith report the
findings.
Materials and Methods
Study population and samples
We recruited 307 students (ages 18 to 35 yrs) from an Australian
university. Students were informed about our study by emailing
flyers, posting on social media through student organisations and
providing information in lectures. Students were approached after
lectures as well as at campus where our data collection room was
set up. Participants were asked to self-complete a paper-based 4-
page questionnaire. Potential participants were informed that the
investigators would not record any identifying details, and that
their anonymity would be preserved. Students who agreed to
participate were given a questionnaire and a tube for collection of
oral rinse sample, both labelled with the same unique identifica-
tion number. The questionnaire covered basic demographics (age,
gender, education etc), sexual behaviour (passionate kissing, giving
and receiving oral sex, and sexual intercourse, numbers of
partners, recency of various sexual activities and sexual orienta-
tion), and alcohol, tobacco and illicit drugs use as well as history of
genital infections, abnormal pap smears and Gardasil vaccination
(the quadrivalent HPV vaccine that protects against HPV types
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HPV-6, -11, -16 and -18 and for which Australia launched a
national program in 2007). It also included two questions about
knowledge of protection from contracting a sexually transmitted
infection from engaging in oral sex. In the questionnaire we
included the following descriptions: ‘one drink’ = a glass of wine,
middy of beer or nip of spirits; ‘Non-smoker’ - You have smoked
100 or fewer cigarettes in your life-time; An ‘illicit drug’ refers to
illegal or controlled substances; ‘Recreational drug’ refers to drugs
used for non-medical purposes, not including cigarettes or alcohol;
‘Passionate kissing’ refers to open-mouthed kissing; ‘Oral sex’
refers to a man’s or woman’s mouth on a partner’s genital area;
‘Sexual intercourse’ refers to vaginal intercourse and anal
intercourse only and does not refer to oral sex; and ‘Mouth
jewellery’ refers to jewellery worn on the lips or tongue requiring
piercing of the skin.
Participants rinsed their mouth with 7 ml sterile saline (0.9%)
for 30 seconds. All oral rinse specimens were frozen at 220uC
within 3 hours of collection. Specimens were later thawed at
ambient room temperature, vortexed and 3 ml was used for DNA
extraction. DNA was extracted in batches of 24 samples at a time,
using the QIAamp DNA Mini Kit following the QIAGEN
supplementary protocol for Isolation of genomic DNA from saliva
and mouthwash (QA19v Jul-10).
Ethics Statement
All participants were given a copy of the Study Information
Sheet; consent was obtained by completing the anonymous
questionnaire. The study was approved by the human research
ethics committees of the Queensland University of Technology
(1200000292) and the QIMR Berghofer Medical Research
Institute (P1508).
HPV DNA analysis
The DNA samples extracted from the participants’ oral rinse
specimens were analysed by PCR for the presence of HPV with
the general mucosal HPV primer GP5+/GP6+ [15]. b-globin
PCR with the primers PCO3 and PCO4 [16] was carried out on
all samples to ensure that no PCR inhibiting agents were present
and that they contained human DNA. The final volume of PCR
solution (25 ml) contained 5 ml of extracted sample DNA, 0.5 mM
of the GP5+ and GP6+ primers or PCO3 and PCO4 primers
(Sigma-Aldrich), dNTPs at concentrations of 0.2 mM each
(Roche), 1 U of AmpliTaq Gold DNA polymerase, 16 PCR
Gold buffer and 2.0 mMMgCl2 (Applied Biosystems). Forty cycles
of amplification was performed on an Eppendorf Mastercycler
Gradient PCR machine after an initial step of 10 minutes
denaturation at 94uC. Each cycle for the GP+ PCR consisted of
94uC for 1 min, 40uC for 2 min and 72uC for 1.5 min, plus a final
elongation step at 72uC for 4 min. Each amplification cycle for the
b-globin PCR consisted of 94uC for 1.5 min, 50uC for 1.5 min
and 72uC for 1.5 min, plus a final elongation step at 72uC for
4 min. In each batch of tests, H2O was used as a negative control.
HeLa cells (HPV-18 positive cervical cell line) were used as a
positive control in both PCR reactions. PCR amplicons were
analysed by electrophoresis (1.5% agarose gel containing ethidium
bromide; SeaKem, FMC bioproducts and Sigma) and identified
under UV light. To minimize the risk for contamination we used
different pipettes and rooms for DNA extraction, preparing the
PCR solution, adding DNA samples to PCR solution and
electrophoresis analysis.
HPV Type Determination
The HPV positive PCR products were purified with the
AgencourtH AMPure PCR purification kit (Agencourt Bioscience)
in a magnetic 96-ring SPRIplateH. The sequencing reaction
contained the purified PCR products together with 3.25 mM of
primer and BigDye Terminator (Applied Biosystems). The
sequencing reaction was performed in an Eppendorf Mastercycler
Gradient PCR machine. After an initial step of 96uC for 2 min, 20
cycles followed, each with 96uC for 10 s, 50uC for 5 s and 60uC
for 2 minutes. The sequence reactions were purified with the
AgencourtH CleanSEQ dye-terminator removal kit (Agencourt
Bioscience) in a magnetic 96-ring SPRIplateH, and purified
sequence reactions were analysed with an automated DNA
sequencer (ABI model 3100). The DNA sequences obtained were
compared with available sequences in GenBank through the
BLAST server (http://blast.ncbi.nlm.nih.gov).
Statistical Analysis
We conducted a sample size calculation for this study, and
concluded that a sample of 300 would be sufficient to detect a
prevalence of 5% with 80% power (expected to observe 15 events,
and would have 95% confidence that the true population
prevalence would be between 2.5 and 7.5%).
We compared HPV positive with HPV negative individuals to
identify characteristics associated with HPV positivity. For
comparisons, we used the t-test for normally distributed contin-
uous variables and for categorical variables we used the x2 test (or
Fischer’s exact test when the expected number in any cell was,5).
Odds ratios (ORs) and 95% confidence intervals (CIs) were
obtained using logistic regression models. For some exposures,
categories were combined to permit effects to be estimated. All
significance tests were two-sided tests at a=0.05. We used SAS
(version 9.2) for all analyses.
Results
Characteristics of the study population
The mean age of the 307 participants was 22.0 years (range 18–
35) and 62% were female. The majority of students (90%; n= 275)
had had some type of sexual contact (including passionate kissing,
oral sex and sexual intercourse) in their lifetime. Of the students
who reported prior sexual activity, 82% (n= 225) had engaged in
oral sex, and 78% (n= 214) had had sexual intercourse. Thirty-
two percent of the participants (n = 98, 95 females, 3 males) had
received at least one dose of the GardasilH vaccine. Table 1
presents characteristics of the study population in detail.
HPV prevalence and HPV types
Seven of the 307 (prevalence 2.3%; 95% confidence interval
0.6–4.0%) students tested positive for oral HPV infection. All the
positive samples had single HPV types detected. The most
prevalent HPV type was HPV-18 which was identified in three
of the seven oral HPV positive individuals (43%). HPV-16, -67, -
69 and -90 were identified in one sample each. All samples tested
positive for b-globin.
Characteristics and behaviour associated with oral HPV
infection
Table 2 shows characteristics and behaviour for HPV positive
and HPV negative individuals in detail. Six of the seven oral HPV
positive individuals were males (p = 0.008). The mean age of the
oral HPV positive group was 23.0 (SD 1.6) and 22.0 (SD 4.0) for
the HPV negative. One of the seven oral HPV positive individuals
reported to have kissed passionately, but had never engaged in oral
sex or had sexual intercourse. Students with oral HPV infection
reported having received oral sex from more partners in their
lifetime (p= 0.0004) as well as in the past year (p = 0.008)
Oral HPV Infections
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compared to HPV negative subjects. Self-reported diagnosis of
HIV was significantly associated with oral HPV infection
(p = 0.023). The following factors were not statistically significantly
associated with oral HPV infection in this sample: age, county of
birth, language spoken at home, secondary school education,
alcohol consumption, illicit drug use, smoking, tonsillectomy,
braces, mouth jewellery, age at first passionate kiss, giving/
receiving oral sex or sexual intercourse, number of partners for
passionate kissing, giving oral sex and sexual intercourse, partners
of same, opposite or mixed sex, previous history of genital
chlamydia, gonorrhoea, HPV or herpes simplex, and use of
condom or dental dam while giving or receiving oral sex. None of
the oral HPV positive subjects reported having had an abnormal
pap smear or had a partner with an abnormal pap smear. None of
Table 1. Selected characteristics of the 307 participants.
Characteristics N (%)
Gender Male 116 (37.8%)
Female 191 (62.2%)




Born in Australia No 83 (27.0%)
Yes 224 (73.0%)
Number of alcoholic drinks per week Less than 1 162 (52.8%)
2 or more 145 (47.2%)
Smoking status Current 19 (6.2%)
Former 34 (11.1%)
Non 254 (82.7%)
Illicit drug use in the last 12months Never 219 (71.3%)
Less than monthly 65 (21.2%)
More than monthly 23 (7.5%)
Ever had any type of sexual contact (including passionate kissing) No 31 (10.1%)
Yes 276 (89.9%)
Ever kissed another person passionately No 31 (10.1%)
Yes 276 (89.9%)
Ever engaged in oral sex No 51 (18.5%)
Yes 224 (81.5%)
Gender of oral sex partner Same sex only 20 (8.9%)
Opposite sex only 193 (85.8%)
Both sexes 12 (5.3%)
Ever given oral sex No 9 (4.0%)
Yes 216 (96.0%)




Very frequently 2 (0.9%)
Ever received oral sex No 11 (4.9%)
Yes 214 (95.1%)
Ever had sexual intercourse No 62 (22.5%)
Yes 214 (77.5%)
Gender of sexual intercourse partners Same sex only 14 (6.5%)
Opposite sex only 190 (88.4%)
Both sexes 11 (5.1%)
Have you ever received the Gardasil vaccine No 199 (65.0%)
Yes 98 (32.0%)
Don’t know 9 (3.0%)
doi:10.1371/journal.pone.0091761.t001
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Table 2. Characteristics of HPV negative and HPV positive individuals.
Characteristics HPV- HPV+ Crude OR
N (%) N (%) (95% CI) P value
Gender Male 110 (36.7%) 6 (85.7%) 1.00 (ref) 0.008
Female 190 (63.3%) 1 (14.3%) 0.10 (0.01–0.81)
Age 18–19 yrs 96 (32.0%) 2 (28.6%) 1.00 (ref)
20–21 79 (26.3%) 1 (14.3%) 0.61 (0.05–6.82)
22–24 65 (21.7%) 1 (14.3%) 0.74 (0.07–8.31)
25–35 60 (20.0%) 3 (42.9%) 2.40 (0.39–14.78) 0.508
Born in Australia No 80 (26.7%) 3 (42.9%) 1.00 (ref) 0.340
Yes 220 (73.3%) 4 (57.1%) 0.48 (0.11–2.21)
Number of alcoholic drinks per week Less than 1 159 (53.0%) 3 (42.9%) 1.00 (ref) 0.595
2 or more 141 (47.0%) 4 (57.1%) 1.50 (0.33–6.83)
Smoking status Non 250 (83.3%) 4 (57.1%) 1.00 (ref) 0.191
Current 18 (6.0%) 1 (14.3%) 3.47 (0.37–32.71)
Former 32 (10.7%) 2 (28.6%) 3.91 (0.69–22.18)
Illicit drug use in the last 12months Never 216 (72.0%) 3 (42.9%) 1.00 (ref) 0.072
Less than monthly 63 (21.0%) 2 (28.6%) 2.29 (0.37–13.98)
More than monthly 21 (7.0%) 2 (28.6%) 6.86 (0.37–13.98)
Ever had any type of sexual contact (including
passionate kissing)
No 31 (10.3%) 0 (0.0%) – 0.370
Yes 269 (89.7%) 7 (100%) –
Number of kissing partners in a lifetime 1 21 (7.9%) 1 (14.3%) 1.00 (ref) 0.504
2–3 55 (20.6%) 1 (14.3%) 0.38 (0.02–6.39)
4–7 59 (22.1%) 0 (0.0%) –
8–15 52 (19.5%) 1 (14.3%) 0.40 (0.02–6.76)
16–28 31 (11.6%) 1 (14.3%) 0.68 (0.04–11.44)
29 or more 49 (18.4%) 3 (42.9%) 1.29 (0.13–13.09)
Ever engaged in oral sex No 50 (18.7%) 1 (14.3%) 1.00 (ref) 0.769
Yes 218 (81.3%) 6 (85.7%) 1.38 (0.16–11.69)
Gender of oral sex partner Same sex only 19 (8.7%) 1 (16.7%) 1.00 (ref)
Opposite sex only 188 (85.8%) 5 (83.3%) 0.50 (0.06–4.55)
Both sexes 12 (5.5%) 0 (0.0%) - 0.686
Ever given oral sex No 9 (4.1%) 0 (0.0%) - 0.612
Yes 210 (95.9%) 6 (100%) -
Number of partners given oral sex to in lifetime 1–7 169 (80.5%) 3 (50.0%) 1.00 (ref) 0.068
8 or more 31 (19.5%) 3 (50.0%) 4.12 (0.80–21.17)
Number of partners given oral sex to in last year None 22 (10.4%) 1 (16.7%) 1.00 (ref) 0.262
1 130 (61.6%) 2 (33.3%) 0.34 (0.03–3.89)
2–3 38 (18.0%) 1 (16.7%) 0.58 (0.03–9.72)
4 or more 21 (10.0%) 2 (33.3%) 2.10 (0.18–24.87)
Use of condom when giving oral sex Never 176 (83.4%) 6 (100%) - 0.880
Seldom 15 (7.1%) 0 (0.0%) -
Occasionally 16 (7.6%) 0 (0.0%) -
Frequently 2 (0.9%) 0 (0.0%) -
Very frequently 2 (0.9%) 0 (0.0%) -
Ever received oral sex No 10 (4.6%) 1 (16.7%) 1.00 (ref) 0.175
Yes 209 (95.4%) 5 (83.3%) 0.24 (0.03–2.24)
Number of partners received oral sex from in lifetime 1 55 (25.8%) 0 (0.0%) - 0.0004
2–3 66 (31.0%) 0 (0.0%) -
4–7 50 (23.5%) 1 (20.0%) 1.00 (ref)
Oral HPV Infections
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the seven students with oral HPV infection had been vaccinated
with GardasilH.
We asked if the participants thought it was possible to get HPV
from engaging in oral sex and 58% answered yes, 3% no, 8% not
impossible, but rare, and 31% were not sure. We also investigated
the knowledge of protection from STIs when engaging in oral sex
and the majority of students (91%) thought that use of male
condom would be protective. Table 3 presents the results of all
means of protection that were included in the questionnaire.
Discussion
Here we investigated the prevalence and determinants of oral
HPV infections in a sample of young Australians. We obtained
DNA samples from oral rinse samples and used PCR primers
(GP+) to detect a wide spectrum of a-papillomaviruses [15], and
found an oral HPV prevalence of 2.3% in our sample. Previous
reports of oral HPV prevalence have varied greatly between
different geographic areas. The largest study on oral HPV
prevalence in the United States, performed by Gillison et al on
5,579 individuals, reported an overall prevalence of 6.9% [10]. In
our study the age group 18–24 years had an oral HPV prevalence
of 1.6% (4/244) and the US study 5.6%, and the age group 25–35
years 5.0% (3/60) compared to 7.1% and 7.3% for the US study’s
age groups 25–29 years and 30–34 years, respectively [10]. The
oral HPV prevalence was lower in our study, but both studies
showed an increasing prevalence with age. The oral a-HPV
prevalences in several American studies have ranged from 3.3% to
25%, but were performed on different populations (16–20 year
olds only, men only and the general population) [10,11,14,17].
One of these studies was conducted in men in Washington (USA)
with a similar age range to our study (18–24 years), and found an
oral HPV prevalence of 7.5% [17]. The oral a-HPV prevalence in
three Scandinavian studies has been lower (1.0%–2.8%), with the
exceptions of one performed at a sexual health clinic for youths,
where it was much higher [7,13,18,19]. Reasons for the different
HPV prevalences reported could be due to different sampling
methods used (rinse with mouthwash or saline, using varying
volumes, as well as using a cytobrush) and some differences in
HPV detection methods used (different PCR primer pairs and
methods for HPV typing (sequencing or arrays)). Aside from these
methodological differences, there may also be true differences in
HPV prevalence between the different populations investigated.
The most commonly detected HPV type in our study was HPV-
18 detected in three of the seven positive samples. HPV-16, -67, -
69 and -90 were isolated in one sample each. HPV-16 and -18 are
both common high-risk HPV types, while HPV-67, -69 and -90
are less commonly reported types isolated from vaginal intraep-
ithelial neoplasia and cervicovaginal cells [20–22]. The reason for
HPV-67, -69 and -90 being less commonly reported could be
because these types are not included in standard HPV assays; it
does not necessarily mean that actual infection is less common.
We found that oral HPV infection was significantly associated
with male gender. This has also been reported in the largest oral
HPV infection population-based study to date, with 10.1% in men
and 3.6% in women [10]. A Swedish study on adolescents found
Table 3. Proportion of positive responses to nominated
measures against STI when engaging in oral sex.
Means of protection yes n (%)
Male condom 279 (91)
Female condom 126 (41)
Cling wrap 15 (5)
Spermicide 5 (2)
Oral sex, not involving ejaculation 18 (6)
Contraceptive patch 5 (2)
Dental dam 72 (23)
Contraceptive pill 7 (2)
Intrauterine device 3 (1)
doi:10.1371/journal.pone.0091761.t003
Table 2. Cont.
Characteristics HPV- HPV+ Crude OR
N (%) N (%) (95% CI) P value
8–15 29 (13.6%) 1 (20.0%) 1.72 (0.10–28.62)
16–28 8 (3.8%) 2 (40.0%) 12.50 (1.01–154.40)
29 or more 5 (2.3%) 1 (20.0%) 10.00 (0.54–185.46)
Number of partners received oral sex from last year None 25 (11.7%) 1 (20.0%) 1.00 (ref) 0.008
1 133 (62.4%) 1 (20.0%) 0.19 (0.01–3.10)
2–3 31 (14.6%) 0 (0.0%) -
4 or more 24 (11.3%) 3 (60.0%) 3.12 (0.30–32.16)
Ever had sexual intercourse No 61 (22.7%) 1 (14.3%) 1.00 (ref) 0.599
Yes 208 (77.3%) 6 (85.7%) 1.76 (0.21–14.90)
No 300 (100%) 6 (85.7%) -
Ever diagnosed with or treated for HIV/AIDS Yes 0 (0.0%) 1 (14.3%) -
No 300 (100%) 6 (85.7%) - 0.023
Have you ever received the Gardasil vaccine No 192 (64.2%) 7 (100%) - 0.146
Yes 98 (32.8%) 0 (0.0%) -
Don’t know 9 (3.0%) 0 (0.0%) -
doi:10.1371/journal.pone.0091761.t002
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that the oral HPV prevalence was higher in young women (3.1%)
compared to men (0.6%) [13], although this difference was not
statistically significant. Male gender has previously been associated
with higher HPV prevalence in HNSCCs [2].
Receiving oral sex was strongly associated with oral HPV
infection in our population, but we found no associations with
passionate kissing, giving oral sex or sexual intercourse (number or
partners or frequency). Several other studies have found oral HPV
infection to be associated with oral sex behaviours, number of
partners as well as frequency [4,14,17,23]. One multi-national
study, of men from U.S., Brazil and Mexico, reported no
association with oral sex and oral HPV prevalence [24].
Self-reported HIV diagnosis was found to be associated with
oral HPV infection. HIV infection has previously been linked with
increased odds ratio of prevalent oral HPV infection [25].
Some U.S studies have reported strong associations between
marijuana use and oral HPV infection, both in healthy popula-
tions and HNSCC patients [4,10], but we found no association
with ever having used illicit drugs and oral HPV status.
About one third of the participants of our study had received
one or more doses of the GardasilH vaccine, and the great majority
of these students were females (95/98). Only one study has
evaluated the effect HPV vaccination has on oral HPV prevalence,
using the bivalent HPV-16/-18 CervarixH in a Costa Rican
population and found that oral HPV prevalence was much lower
in the vaccinated population after 4 years follow-up [26]. None of
the oral HPV positive individuals in our sample were GardasilH
vaccinated. Four of the oral HPV positive students had infections
with HPV-16 and -18, which potentially could have been
prevented by HPV vaccination.
Strengths of the current study include the collection of detailed
lifestyle and sexual behaviour information from all participants.
Also, a sensitive technique was used for determining the presence
of a-HPV DNA in the oral rinse samples. However, while the
sample was relatively large, the prevalence of oral HPV was low,
and our study was underpowered to fully explore associations with
all possible explanatory factors. While few of the associations were
statistically significant, the magnitude and direction of the
associations are plausible with current knowledge, and should be
examined in larger datasets or through meta-analysis. In addition,
our sample was recruited from a single tertiary education
institution, and thus while our findings cannot be generalised to
all Australians in the same age group, we believe they are likely to
reflect the experiences of those in similar settings.
In conclusion, we found that oral HPV prevalence was low in
this sample of young Australians. Oral HPV infection was found to
be associated with male gender, receiving oral sex and self-
reported diagnosis of HIV. Given the low HPV DNA prevalence
in this study, larger studies are required both in Australia and
internationally to determine oral HPV infection in the general
population.
Acknowledgments
We would like to thank the participants of this study.
Author Contributions
Conceived and designed the experiments: AA DW MC MPD. Performed
the experiments: AA MC SP MD. Analyzed the data: AA DW.
Contributed reagents/materials/analysis tools: AA DW. Wrote the paper:
AA DW MC MD SP MPD.
References
1. Attner P, Nasman A, Du J, Hammarstedt L, Ramqvist T, et al. (2012) Survival
in patients with human papillomavirus positive tonsillar cancer in relation to
treatment. Int J Cancer 131: 1124–1130.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, et al. (2011)
Human papillomavirus and rising oropharyngeal cancer incidence in the United
States. J Clin Oncol 29: 4294–4301.
3. Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, et al. (2009) Incidence
of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm,
Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 125: 362–366.
4. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, et al. (2008) Distinct risk
factor profiles for human papillomavirus type 16-positive and human
papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst
100: 407–420.
5. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, et al. (2000)
Evidence for a causal association between human papillomavirus and a subset of
head and neck cancers. J Natl Cancer Inst 92: 709–720.
6. Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, et al. (2010) Squamous
cell carcinoma of the oropharynx in Australian males induced by human
papillomavirus vaccine targets. Vaccine 28: 3269–3272.
7. Du J, Nordfors C, Ahrlund-Richter A, Sobkowiak M, Romanitan M, et al.
(2012) Prevalence of oral human papillomavirus infection among youth,
Sweden. Emerg Infect Dis 18: 1468–1471.
8. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, et al. (2007) Case-
control study of human papillomavirus and oropharyngeal cancer. N Engl J Med
356: 1944–1956.
9. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus
types in head and neck squamous cell carcinomas worldwide: a systematic
review. Cancer Epidemiol Biomarkers Prev 14: 467–475.
10. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, et al. (2012)
Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307:
693–703.
11. Bottalico D, Chen Z, Dunne A, Ostoloza J, McKinney S, et al. (2011) The oral
cavity contains abundant known and novel human papillomaviruses from the
Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis 204: 787–
792.
12. Kurose K, Terai M, Soedarsono N, Rabello D, Nakajima Y, et al. (2004) Low
prevalence of HPV infection and its natural history in normal oral mucosa
among volunteers on Miyako Island, Japan. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod 98: 91–96.
13. Nordfors C, Grun N, Haeggblom L, Tertipis N, Sivars L, et al. (2013) Oral
human papillomavirus prevalence in high school students of one municipality in
Sweden. Scand J Infect Dis.
14. Pickard RK, Xiao W, Broutian TR, He X, Gillison ML (2012) The prevalence
and incidence of oral human papillomavirus infection among young men and
women, aged 18–30 years. Sex Transm Dis 39: 559–566.
15. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders
PJ (1995) The use of general primers GP5 and GP6 elongated at their 3’ ends
with adjacent highly conserved sequences improves human papillomavirus
detection by PCR. J Gen Virol 76: 1057–1062.
16. de Roda Husman AM, Walboomers JM, Hopman E, Bleker OP, Helmerhorst
TM, et al. (1995) HPV prevalence in cytomorphologically normal cervical
scrapes of pregnant women as determined by PCR: the age-related pattern.
J Med Virol 46: 97–102.
17. Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, et al. (2012) Rates
and determinants of oral human papillomavirus infection in young men. Sex
Transm Dis 39: 860–867.
18. Forslund O, Johansson H, Madsen KG, Kofoed K (2013) The nasal mucosa
contains a large spectrum of human papillomavirus types from the Betapapillo-
mavirus and Gammapapillomavirus genera. J Infect Dis 208: 1335–1341.
19. Hansson BG, Rosenquist K, Antonsson A, Wennerberg J, Schildt EB, et al.
(2005) Strong association between infection with human papillomavirus and oral
and oropharyngeal squamous cell carcinoma: a population-based case-control
study in southern Sweden. Acta Otolaryngol 125: 1337–1344.
20. Kino N, Sata T, Sato Y, Sugase M, Matsukura T (2000) Molecular cloning and
nucleotide sequence analysis of a novel human papillomavirus (Type 82)
associated with vaginal intraepithelial neoplasia. Clin Diagn Lab Immunol 7:
91–95.
21. Kirii Y, Matsukura T (1998) Nucleotide sequence and phylogenetic classification
of human papillomavirus type 67. Virus Genes 17: 117–121.
22. Terai M, Burk RD (2002) Identification and characterization of 3 novel genital
human papillomaviruses by overlapping polymerase chain reaction:
candHPV89, candHPV90, and candHPV91. J Infect Dis 185: 1794–1797.
23. D’Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML (2009) Oral sexual
behaviors associated with prevalent oral human papillomavirus infection. J Infect
Dis 199: 1263–1269.
24. Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, et al. (2011)
The epidemiology of oral HPV infection among a multinational sample of
healthy men. Cancer Epidemiol Biomarkers Prev 20: 172–182.
Oral HPV Infections
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e91761
25. Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, et al.
(2012) Risk factors for oral HPV infection among a high prevalence population
of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers
Prev 21: 122–133.
26. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, et al. (2013)
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after
Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS
One 8: e68329.
Oral HPV Infections
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e91761
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.
